canada clinical guidance

Chronic kidney disease

A Canadian clinical summary of chronic kidney disease, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. British Columbia is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.

British Columbia source: bounded use

Chronic Kidney Disease: Identification, Evaluation and Management of Adult Patients supplies a Canadian implementation example for this summary. It must not be presented as the rule outside British Columbia.
sources for this section:BC CKD

Source-attributed clinical priorities

  • Identify chronic kidney disease using both estimated GFR and urine albumin-to-creatinine ratio, confirmed over time when the presentation is not acute.
  • Review reversible causes, medication safety and cardiovascular risk while staging kidney and albuminuria severity.
  • Escalate rapidly for acute deterioration and use the jurisdiction鈥檚 nephrology referral criteria for persistent high-risk disease.
  • Use kidney and albuminuria categories together to communicate prognosis and follow-up intensity.
sources for this section:BC CKD

Practical assessment and management workflow

1
Repeat eGFR and urine ACR after an appropriate interval to establish chronicity.
2
Review blood pressure, diabetes, cardiovascular risk, urinalysis, ultrasound indications and nephrotoxic medicines.
3
Apply kidney-protective therapy and dose adjustment to the documented eGFR and albuminuria phenotype.
4
Trend eGFR and ACR and refer rapid progression, high-risk disease or uncertain cause.
sources for this section:BC CKD

Safety, red flags and urgent escalation

  • Escalate hyperkalemia, pulmonary edema, uremic complications or rapidly falling kidney function.
  • Avoid NSAIDs and review contrast, dehydration and sick-day medicine risk.
  • Use the nephrology criteria of the patient鈥檚 province rather than the BC referral route outside BC.
sources for this section:BC CKD

Confirm the local pathway before acting

British Columbia is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:BC CKD

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:BC CKD

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Government of British ColumbiaChronic Kidney Disease: Identification, Evaluation and Management of Adult Patientsaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.